Open Access
Cardiac Surgery : from a stabbing in the chest to the artificial heart
None
Open Access
Hemodynamics : from De Motu Cordis to intracoronary stents
None
Open Access
Autonomic biology: From beheaded animals to a spate of nobel prizes
Gary S. Francis,
Wai (Wilson) Hong Tang
None
Open Access
Genetics and molecular biology: From a monastery garden to rebuilding the heart
None
Open Access
Ischemic Heart Disease : from a sudden death in Chicago to fibrinolysis and angioplasty
None
Open Access
When and why should we employ the interventional cardiologist
None
Open Access
Electrophysiology : from Galvani's frog to the implantable defibrillator
Michael R. Rosen,
Michiel J. Janse
None
Open Access
Summaries of ten seminal papers
None
Open Access
Hypertension : from a mare in Cambridgeshire to the South-American pit viper
None
Open Access
Myocardial reperfusion: Biology, benefits and consequences
James T. Willerson,
L. Maximilian Buja
None
Open Access
Heart Failure : from Hippocrates and Harvey to molecular biology
None
Open Access
Can If inhibition help after myocardial infarction
Guillaume Martin,
Jean-Claude Tardif
None
Open Access
Atherosclerosis : from Egyptian mummies to immunemediated intraplaque inflammation
None
Open Access
How will genomic approaches translate into clinical applications in sudden cardiac death
None
Open Access
How can we reduce sudden death in the community
Graham Nichol,
Myron L. Weisfeldt
None
Open Access
Sudden cardiac death : risk factors, treatment, and prevention
A wide range of cardiac etiologies give rise to sudden cardiac death (SCD), the commonest being coronary artery disease, cardiomyopathy, and inherited arrhythmogenic disorders. Improved primary and secondary preventive pharmacotherapy, device therapy, lifestyle changes, and genetic profiling have had a major impact on the prediction and prevention of SCD. By far the best preventive strategy is to inhibit the development of electrophysiological substrates giving rise to ventricular tachyarrhythmias. A significant role in this regard has been played by nonantiarrhythmic drug therapy designed to avoid and reverse substrate remodeling and inappropriate substrate modulation by the autonomic nervous system. Improved resuscitation and defibrillation techniques, together with advances in implantable pacemaker and defibrillator technology, have all improved treatment outcome. Much recent research has been directed at profiling patients most likely to benefit from implantable cardioverter defibrillator therapy. Early experience with new safer and more specific antiarrhythmic pharmacotherapy has already shown benefits. Although SCD can now be effectively predicted, prevented, and treated, the burden of cardiovascular disease is rising again, making the availability of cost-effective therapy for life-threatening ventricular arrhythmias an increasingly significant challenge.
Open Access
Can If inhibition help in congestive heart failure
Luigi Tavazzi,
Alessandro Mugelli
None
Open Access
The control of heart rate: the physiology of the sinoatrial node and the role of the I f current
D.J. Hearse,
R. Ferrari,
Michael J. Shattock,
M. R. Rosen
None
